Edition:
United States

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

2.16CAD
28 Apr 2017
Change (% chg)

$0.03 (+1.41%)
Prev Close
$2.13
Open
$2.17
Day's High
$2.20
Day's Low
$2.14
Volume
1,208,775
Avg. Vol
1,807,001
52-wk High
$3.47
52-wk Low
$1.47

Latest Key Developments (Source: Significant Developments)

Fda confirms Prometic's PBI-4050 IPF clinical trial design
Tuesday, 18 Apr 2017 07:00am EDT 

April 18 (Reuters) - Prometic Life Sciences Inc :FDA confirms Prometic's PBI-4050 IPF clinical trial design.Prometic Life Sciences Inc - Prometic to also conduct placebo controlled phase 2/3 PBI-4050 monotherapy clinical trial.Prometic Life Sciences Inc - FDA concurs with add-on placebo controlled phase 2/3 clinical trial for PBI-4050 in combination with Nintedanib.  Full Article

Prometic Life Sciences has received a $9.5 mln purchase order for supply of affinity resin to an existing client
Friday, 7 Apr 2017 07:00am EDT 

Prometic Life Sciences Inc : Has received a $9.5 million purchase order for supply of affinity resin to an existing client . The purchase order is part of an ongoing license and long-term supply agreement already secured with the client .Affinity resin will be supplied to the client starting in second half of 2017 and continuing throughout 2018.  Full Article

Prometic completes filing of its plasminogen Biologics license application with U.S. FDA
Wednesday, 5 Apr 2017 06:00am EDT 

Prometic Life Sciences Inc : Prometic completes the filing of its plasminogen Biologics license application ("BLA") with the U.S. FDA .Prometic Life Sciences Inc - "we look forward to launching Plasminogen in USA in Q4 2017".  Full Article

Prometic says net loss for Q4 was $40.1 million
Thursday, 30 Mar 2017 10:48pm EDT 

Prometic Life Sciences Inc : Prometic reports its 2016 fourth quarter and year end highlights and financial results . Q4 revenue c$4.1 million versus c$14.1 million . Q4 revenue view c$5.3 million -- Thomson Reuters I/B/E/S .Prometic life sciences - net loss for q4 was $40.1 million compared to a net loss of $12.3 million last year.  Full Article

Prometic Life Sciences Inc entered into a binding memorandum of terms with Shenzhen Royal Asset Management
Thursday, 30 Mar 2017 07:00am EDT 

Prometic Life Sciences Inc : Prometic Life Sciences Inc - entered into a binding memorandum of terms with Shenzhen Royal Asset Management to establish a joint venture . Prometic Life Sciences Inc - prometic to own 75pct of joint venture following SRAM'S $33 million investment . Prometic Life Sciences - to establish JV for development, manufacture and commercialization of PBI-4050, PBI-4547 and PBI-4425 in China . Prometic Life Sciences - SRAM will provide $23 million in 2017, to secure an initial 17pct ownership of prometic chinaco .Prometic Life Sciences Inc - SRAM will have right to increase ownership in prometic chinaco to up to 25pct with further $10 million investment.  Full Article

Prometic enters into binding agreement to secure $25 million follow-on financing from structured Alpha LP
Friday, 24 Mar 2017 06:30am EDT 

Prometic Life Sciences Inc : Prometic enters into binding agreement to secure $25 million follow-on financing from structured Alpha LP, an affiliate of Thomvest Asset Management Inc . Prometic Life Sciences Inc - $25 million debt financing to bear interest of 8.5pct per annum and repayable in July, 2022 . Prometic Life Sciences Inc - proceeds received by prometic from aggregate exercise of all of warrants would be sufficient to repay loan in its entirety .Prometic Life Sciences -as partial consideration for loan, co will grant structured Alpha LP 10.6 million warrants with an exercise price of $3.70 per share.  Full Article

Prometic says FDA grants orphan drug designation to its PBI-4050 drug
Friday, 3 Mar 2017 06:30am EST 

Prometic Life Sciences Inc : US FDA grants orphan drug designation to Prometic's PBI-4050 drug for the treatment of alström syndrome .Prometic Life Sciences - currently investigating effects of PBI-4050 on multiple organs in as patients in ongoing, open label, phase 2, clinical study in UK.  Full Article

Prometic says PBI-4050 shows encouraging efficacy in IPF study
Wednesday, 22 Feb 2017 06:30am EST 

Prometic Life Sciences Inc : Prometic's PBI-4050 continues to demonstrate early evidence of efficacy following completion of idiopathic pulmonary fibrosis phase 2 clinical trial . Prometic life sciences inc - early evidence of efficacy of pbi-4050 as a monotherapy and in combination with one of commercially available drugs confirmed . Prometic life sciences inc - pbi-4050 continues to be very well tolerated, whether used alone or in combination with nintedanib or pirfenidone .Prometic life sciences inc - intend to initiate in q2 2017 pivotal phase 2/3 ipf clinical trial.  Full Article

ProMetic Life Sciences says California Capital Equity acquires 44 mln of co's shares
Monday, 6 Feb 2017 06:30am EST 

ProMetic Life Sciences Inc : California Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants .California Capital Equity has exercised 44.8 million share purchase warrants at price of $0.47 per share for total proceeds of $21.1 million.  Full Article

Prometic reacquires plasminogen rights from Hematech
Thursday, 5 Jan 2017 06:30am EST 

Prometic Life Sciences Inc : Prometic reacquires plasminogen rights from Hematech . Prometic Life Sciences Inc - regains 100 pct ownership of profits from future sales of plasminogen for congenital deficiency . Prometic Life Sciences Inc - hematech continues to hold taiwanese rights to ppps™ as cmo supplier to prometic . Prometic Life Sciences Inc - consideration for acquiring rights included issuance of 1.7 million shares of prometic to Hematech . Prometic Life Sciences Inc - amended its licensing agreement originally entered into with Hematech Biotherapeutics Inc in May 2012 .Prometic Life Sciences Inc - consideration included payment of mid-single digit royalty as well as other non-cash considerations to license agreement.  Full Article

More From Around the Web

BRIEF-ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial

* ProMetic's PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial Source text for Eikon: Further company coverage: